False positives in dog cannabis tests reveal hidden metabolite problem

This research tackles an important diagnostic problem in veterinary medicine: enzyme immunoassays (EIAs) commonly used to detect THC metabolites in dog urine are returning false positive results. When these positive samples are analyzed using more precise methods like gas chromatography-mass spectrometry (GC-MS), they often test negative. This discrepancy suggests the immunoassays are reacting to compounds other than the expected THC breakdown products, raising serious concerns about misdiagnosis of canine cannabis intoxication.

Researchers identified the culprit: novel metabolites derived from THCV (tetrahydrocannabivarin), a cannabinoid that's increasingly appearing in consumer cannabis products. Using advanced analytical techniques, they discovered two previously unknown compounds with molecular weights of 446 and 460 that cross-react with the standard THC-COOH antibodies. These THCV metabolites are structurally distinct from traditional THC breakdown products yet fool the immunoassay into producing positive results. This finding is particularly significant given growing commercial interest in THCV-containing cannabis products.

The practical implications are substantial for both veterinary diagnostics and cannabis regulation. False positives in dog toxicology cases could lead to unnecessary treatment or misdiagnosis of intoxication severity. The study reveals fundamental limitations in current immunoassay-based screening protocols when facing an increasingly diverse cannabinoid marketplace. These findings underscore the critical need for updated diagnostic methods that account for the full spectrum of cannabis metabolites now present in consumer products.